Enovis Corporation (NYSE:ENOV) Receives Consensus Rating of "Buy" from Analysts

Key Points

• Analyst consensus: Nine analysts have a consensus Buy rating on Enovis (1 sell, 6 buy, 2 strong buy) with an average 12‑month price target of $47.43.
• Insider and institutional ownership: Insider Oliver Engert bought 1,000 shares at $25.50 on Feb 27 (insiders bought 5,000 shares in the last three months) and insiders own 2.70% of the stock while institutional investors own 98.45%.
• Earnings and guidance: Enovis reported a quarterly EPS beat ($0.95 vs. $0.81 estimate) but slightly missed revenue ($575.76M vs. $584.30M), and set FY2026 guidance of $3.520–$3.730 EPS versus sell‑side forecasts of $2.79 for the current fiscal year.

Enovis Corporation (NYSE:ENOV - Get Free Report) has earned a consensus rating of "Buy" from the nine analysts that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $47.4286.

A number of equities analysts recently commented on the company. Canaccord Genuity Group decreased their price target on Enovis from $58.00 to $50.00 and set a "buy" rating for the company in a research note on Wednesday, December 17th. Needham & Company LLC lifted their price target on Enovis from $49.00 to $52.00 and gave the stock a "buy" rating in a research note on Thursday, February 26th. Evercore reiterated an "outperform" rating on shares of Enovis in a research note on Monday, January 12th. Zacks Research upgraded Enovis from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, March 4th. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Enovis in a research report on Friday.

Insider Buying and Selling

In related news, insider Oliver Engert bought 1,000 shares of the firm's stock in a transaction on Friday, February 27th. The stock was bought at an average cost of $25.50 per share, for a total transaction of $25,500.00. Following the completion of the purchase, the insider directly owned 43,640 shares in the company, valued at approximately $1,112,820. The trade was a 2.35% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders purchased 5,000 shares of company stock valued at $121,983 in the last three months. Insiders own 2.70% of the company's stock.

Hedge Funds Weigh In On Enovis

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Impax Asset Management Group plc boosted its stake in Enovis by 47.5% in the third quarter. Impax Asset Management Group plc now owns 310,630 shares of the company's stock valued at $9,425,000 after acquiring an additional 100,000 shares during the period. Allspring Global Investments Holdings LLC boosted its stake in Enovis by 11.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 757,673 shares of the company's stock valued at $20,086,000 after acquiring an additional 78,497 shares during the period. Assenagon Asset Management S.A. acquired a new position in Enovis in the third quarter valued at approximately $4,045,000. Vanguard Group Inc. boosted its stake in Enovis by 2.0% in the third quarter. Vanguard Group Inc. now owns 6,524,235 shares of the company's stock valued at $197,945,000 after acquiring an additional 125,460 shares during the period. Finally, Osaic Holdings Inc. boosted its stake in Enovis by 56.0% in the second quarter. Osaic Holdings Inc. now owns 139,727 shares of the company's stock valued at $4,382,000 after acquiring an additional 50,156 shares during the period. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis Stock Up 1.0%

NYSE:ENOV opened at $25.10 on Wednesday. The company has a market capitalization of $1.44 billion, a price-to-earnings ratio of -1.21 and a beta of 1.47. Enovis has a one year low of $21.00 and a one year high of $37.85. The stock has a 50-day simple moving average of $23.20 and a 200 day simple moving average of $26.47. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.04 and a current ratio of 2.02.

Enovis (NYSE:ENOV - Get Free Report) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.95 EPS for the quarter, topping analysts' consensus estimates of $0.81 by $0.14. The business had revenue of $575.76 million during the quarter, compared to the consensus estimate of $584.30 million. Enovis had a positive return on equity of 8.74% and a negative net margin of 52.69%.The company's revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period last year, the firm earned $0.98 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Sell-side analysts predict that Enovis will post 2.79 EPS for the current fiscal year.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.